The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Beam Therapeutics Inc shares valued at $991,667 were sold by FMR LLC on Jul 30 ’25. At $20.50 per share, FMR LLC sold 48,374 shares. The insider’s holdings dropped to 2,073,665 shares worth approximately $37.04 million following the completion of this transaction.
Also, Simon Amy sold 876 shares, netting a total of over 17,625 in proceeds. Following the sale of shares at $20.12 each, the insider now holds 64,864 shares.
Before that, Simon Amy had sold 374 shares from its account. In a trade valued at $6,336, the Chief Medical Officer traded Beam Therapeutics Inc shares for $16.94 each. Upon closing the transaction, the insider’s holdings decreased to 374 shares, worth approximately $1.17 million.
As published in a research note from BofA Securities on March 28, 2025, Beam Therapeutics Inc [BEAM] has been rated up from a Neutral to a Buy and the price target has been revised to $42. Analysts at Scotiabank upgraded the stock from ‘”a Sector perform”‘ to ‘”a Sector outperform”‘ outlook in a report released in early March. As of January 29, 2025, Cantor Fitzgerald has increased its “Neutral” rating to a “an Overweight” for BEAM. Earlier on November 06, 2024, Leerink Partners upgraded its rating. Their new recommendation was “an Outperform” for BEAM stock which previously was a “a Market perform”.
Analyzing BEAM Stock Performance
On last trading session, Beam Therapeutics Inc [NASDAQ: BEAM] plunged -2.40% to $17.86. The stock’s lowest price that day was $17.58, but it reached a high of $18.42 in the same session. During the last five days, there has been a drop of approximately -9.39%. Over the course of the year, Beam Therapeutics Inc shares have dropped approximately -30.26%.
Is Beam Therapeutics Inc subject to short interest?
Stocks of Beam Therapeutics Inc saw a sharp rise in short interest on 2025-07-15 jumping by 1.93 million shares to 23.66 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 21.73 million shares. A jump of 8.16% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.87 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.87.
Which companies own the most shares of Beam Therapeutics Inc (BEAM)?
In terms of Beam Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 40 in the next 12 months, up nearly 118.58% from the previous closing price of $18.3. Analysts anticipate Beam Therapeutics Inc stock to reach 55 by 2025, with the lowest price target being 25. In spite of this, 6 analysts ranked Beam Therapeutics Inc stock as Buy at the end of 2025.
